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Simple Summary: In this study, we investigated the expression pattern and prognostic significance
of the heat shock proteins (HSPs) family members in breast cancer (BC) by using several bioinfor-
matics tools and proteomics investigations. Our results demonstrated that, collectively, HSPs were
deregulated in BC, acting as both oncogene and onco-suppressor genes. In particular, two different
HSP-clusters were significantly associated with a poor or good prognosis. Interestingly, the HSPs
deregulation impacted gene expression and miRNAs regulation that, in turn, affected important bio-
logical pathways involved in cell cycle, DNA replication, and receptors-mediated signaling. Finally,
the proteomic identification of several HSPs members and isoforms revealed much more complexity
of HSPs roles in BC and showed that their expression is quite variable among patients. In conclusion,
we elaborated two panels of HSPs that could be further explored as potential biomarkers for BC
progression and prognosis.
Abstract: Heat shock proteins (HSPs) are a well-characterized molecular chaperones protein family,
classified into six major families, according to their molecular size. A wide range of tumors have
been shown to express atypical levels of one or more HSPs, suggesting that they could be used as
biomarkers. However, the collective role and the possible coordination of HSP members, as well as
the prognostic significance and the functional implications of their deregulated expression in breast
cancer (BC) are poorly investigated. Here, we used a systematic multi-omics approach to assess
the HSPs expression, the prognostic value, and the underlying mechanisms of tumorigenesis in
BC. By using data mining, we showed that several HSPs were deregulated in BC and significantly
correlated with a poor or good prognosis. Functional network analysis of HSPs co-expressed genes
and miRNAs highlighted their regulatory effects on several biological pathways involved in cancer
progression. In particular, these pathways concerned cell cycle and DNA replication for the HSPs
co-expressed genes, and miRNAs up-regulated in poor prognosis and Epithelial to Mesenchymal
Transition (ETM), as well as receptors-mediated signaling for the HSPs co-expressed genes up-
regulated in good prognosis. Furthermore, the proteomic expression of HSPs in a large sample-set
of breast cancer tissues revealed much more complexity in their roles in BC and showed that their
expression is quite variable among patients and confined into different cellular compartments.
In conclusion, integrative analysis of multi-omics data revealed the distinct impact of several HSPs
members in BC progression and indicate that collectively they could be useful as biomarkers and
therapeutic targets for BC management.
Keywords: breast cancer; HSPs; expression; prognosis; data mining; proteomics; miRNAs
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1. Introduction
Breast cancer (BC) represents the most common type and the leading cause of death
of cancer among females and accounts for ~16% of all cancers [1]. The etiology of BC is
quite complex, involving several genetic and epigenetic changes [2]. Consequently, breast
cancer is a heterogeneous disease with several subtypes of different cellular compositions,
molecular alterations, as well as clinical behavior [3,4]. Several factors, such as histological
grade, type and size of the tumor, lymph node metastasis, estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth factor receptor 2 (HER), are generally
considered as prognostic factors, but are insufficient to provide useful information for clini-
cal management [5,6]. Despite the achieved improvements, the prognosis of BC patients is
still a poor predictor and the identification of more reliable biomarkers must be explored.
Heat shock proteins (HSPs) are one of the largest groups of molecular chaperones that
assist the correct folding of partially folded or denatured proteins and prevent the forma-
tion of potential aggregates in the cells, promoting their proteasomal degradation [7]. HSPs
were first discovered as stress-inducible proteins against physical (temperature elevation)
or chemical (increase or decrease in pH, salinity, or oxygen concentration) stressors, per-
forming a wide range of functional activities: Modulation of their synthesis, regulation of
kinases activation, participation in signal transduction pathways and rRNA processing [8].
Under physiological conditions, HSPs perform chaperone functions on a broad array of
client proteins, including transcription factors, nuclear hormone receptors, viral proteins
and signaling mediators. Depending on their molecular weight and main functions, six
major subfamilies of HSPs have been reported: HSP110, HSP90, HSP70, HSP60 (chaper-
onins), HSP40 (DNAJ-class proteins), and HSP20 (small heat shock proteins) [9]. Within
each subfamily, some members are constitutively expressed, inducible regulated, and/or
targeted to different compartments [7,10,11]. Genes encoding HSPs are also transcription-
ally regulated by a variety of physiologic processes not typically associated with cell stress,
including cell cycle, cell proliferation, and differentiation [12].
Aberrant expression of HSPs has been reported in a wide range of human tumors,
including breast, endometrial, ovarian, colon, lung, and prostate [13,14]. In cancer cells, the
HSPs network is extensively remodeled and could participate in the functional metabolism
of tumor cells, protect them from harmful factors, provide an immunogenic context and
allow tumor cells to tolerate genetic alterations, which would otherwise be fatal [15–17].
The expression of HSPs has been associated with tumor cell proliferation and differentiation,
as well as with resistance to apoptosis and poor prognosis [18]. These observations, while
intriguing, have not resolved whether the association between cancer evolution and HSPs
is causal or correlative.
Here, we aimed to more precisely estimate the relationship between HSP expres-
sion and prognosis in breast cancer, and highlight the functional implications of their
deregulation by using a multi-omics integrative analysis.
An in silico analysis on differential expression of HSP family members in breast and
other tumors was firstly performed, and the differentially expressed members (50 up-
regulated and 26 down-regulated) were checked for genetic alterations and promoter
methylation status. The prognostic value of HSP members and association with clinical
variables were also assessed. Next, to highlight the important biological pathways dereg-
ulated as a consequence of HSPs expression, the lists of HSPs co-expressed genes and
miRNAs extracted by different cross-platforms were used to perform functional analyses.
Finally, proteomics investigations on a large sample set of breast cancer tissues showed
additional complexity of the HSPs network in BC, with different protein isoforms identified
for each HSP gene, probably performing additional functions and/or interactions. Our find-
ings identified two distinct HSP-clusters with opposite functions in breast cancer: The first
one with 19 members, was significantly associated with a poor prognosis and affected both
cell cycle and DNA replication. The second HSP-cluster included 10 members associated
with good prognosis, presumably affecting receptor signaling and Epithelial to Mesenchy-
mal Transition (ETM). Interestingly, the HSPs-network involved also several miRNAs and
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protein isoforms that, in turn, could add new perspectives on HSPs contribution to BC. To
the best of our knowledge, this is the first attempt exploring the potential mechanisms of
the HSPs-mRNAs-miRNAs-proteins network, underlining that HSP-based regulation of
BC progression is a multi-level process. We propose that the identified HSP-clusters can be
used to stratify patients according to their predicted clinical outcome.
2. Materials and Methods
2.1. Expression Analysis of HSP Members Using UALCAN and Oncomine
The mRNA expression levels of each HSP member in tumors and their normal tissue
counterparts were analyzed using UALCAN (https://ualcan.path.uab.edu/, accessed
date 26 February 2021) and Oncomine database (https://www.oncomine.org/resource/
login.html, accessed date 26 February 2021). UALCAN is a comprehensive, user-friendly,
and interactive web resource for analyzing cancer OMICS data (TCGA, MET500, and
CPTAC) [19]. For each query, the database provides graphs and plots depicting the
expression profile of protein and miRNAs between normal and cancer tissues and evaluates
epigenetic regulation of gene expression by promoter methylation. The expression level
of HSP members was normalized as transcript per million reads, and a p-value of no
more than 0.01 calculated through the Student’s t-test was considered to be significant.
Oncomine, an online microarray database, can analyze the mRNA expression differences
between tumor and normal tissues in 20 different human cancers. The thresholds were set
as follows: p-value: 0.01; fold change: 2; gene rank: 10%; analysis type: cancer vs. normal
analysis; data type: mRNA.
2.2. Genetic Alterations and Epigenetic Regulation of HSP Members Using cBioPortal
and UALCAN
The frequency of HSPs alterations (amplification, deep deletion, and missense muta-
tions) in BC patients was assessed using the OncoPrint tool of cBioPortal (http://www.
cbioportal.org, accessed date 26 February 2021). cBioportal is an interactive open-source
platform, that provides large-scale cancer genomics data sets database [20]. Promoter
methylation status was analyzed using UALCAN.
2.3. Evaluation of the Prognostic Value of HSP Members Using KM Plotter Database and Human
Protein Atlas
The correlation between the mRNA expression levels of HSP members and the sur-
vival probability of BC patients was analyzed using the Kaplan-Meier Plotter database
(http://kmplot.com/analysis/, accessed date 26 February 2021) [21]. For each HSP gene,
Distant Metastasis Free Survival (DMFS), Overall Survival (OS), and Relapse Free Survival
were assessed. The Affimetrix ID probes were entered into the database by using the
multigene classifier. Patients were divided into high and low expression groups by using
the best cutoff of mRNA expression. The database provided statistical plots for individual
genes. The correlation between HSPs protein expression levels via immunohistochemistry
analysis and overall survival of BC patients was analyzed using the Human Protein At-
las (https://www.proteinatlas.org/, accessed date 26 February 2021) [22]. For each HSP
protein, the immunohistochemical staining was evaluated and scored based on staining
intensity (negative, weak, moderate, or strong) and the fraction of stained cells (<25%,
25~75%, >75%). The staining quantity of each protein via IHC was determined as the
percentage of stained cells in 10 high-power fields. All annotation data and immunohisto-
chemistry images analyzed in the present investigation and all anti-body validation data
are publicly available at https://www.proteinatlas.org/, accessed date 26 February 2021.
2.4. Relationship between HSP Members and Clinical-Pathological Parameters Using
Bc-GenExMiner and GOBO
The correlation between the mRNA expression of HSP members and different clinical-
pathological parameters, such as ER/PR/HER receptor status and lymph node (N) involve-
ment, were evaluated using the Breast cancer Gene-Expression Miner v4.5 database (bc-
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GenExMiner v4.5) [23], an on-line statistical mining tool (http://bcgenex.ico.unicancer.fr,
accessed date 26 February 2021) of published annotated BC transcriptomic data (DNA
microarrays [n = 10,716] and RNA-seq [n = 4712]). bcGenExMiner offers the possibility to
explore gene expression, prognostic and correlation analyses, providing various kinds of
plots. The association between HSP members and grading (G1/G2/G3) was performed by
Gene expression-based Outcome for Breast cancer Online (GOBO database) [24]. GOBO
(http://co.bmc.lu.se/gobo, accessed date 26 February 2021) enables a rapid assessment of
gene expression levels, the identification of co-expressed genes and association with the
outcome for single genes, gene sets, or gene signatures in an 1881-sample breast cancer
data set, generated on Affymetrix U133A microarrays.
2.5. Analysis of HSPs Co-Expressed Genes and Pathways Enrichment Analysis
The co-expression profiles of the HSPs associated with poor and good prognosis
were retrieved using three different online platforms, namely UALCAN (https://ualc
an.path.uab.edu/, accessed date 26 February 2021), GOBO (http://co.bmc.lu.se/gobo/
coexpressed_genes.pl, accessed date 26 February 2021) and bcGenExMiner (http://bcgenex.
centregauducheau.fr/BC-GEM/GEM-Requete.php?mode=5, accessed date 26 February
2021). Results were statistically analyzed using Pearson’s correlation coefficient (p ≥ 0.4
and p ≤ −0.4). Positive and negative HSPs co-expressed genes were properly sorted to
obtain two lists of up-regulated genes in poor prognosis (positive co-expressed genes for
HSPs correlated with poor prognosis and negative co-expressed genes for HSPs correlated
with good prognosis) and up-regulated in good prognosis (positive co-expressed genes
for HSPs correlated with good prognosis and negative co-expressed genes for HSPs corre-
lated with poor prognosis). Each gene list was submitted into the FunRich database [25],
(http://www.funrich.org/, accessed date 26 February 2021) a stand-alone software tool
used mainly for functional enrichment and interaction network analysis of genes and miRNA.
Enriched biological pathways were ranked by p-value and the top six significant pathways
were exhibited as bar charts. A p-value < 0.05 was regarded as statistically significant.
2.6. Interactome Construction Using STRING Database
STRING (https://string-db.org, accessed date 26 February 2021) is a database of
known and predicted protein-protein interactions. The interactions include direct (physical)
and indirect (functional) associations derived from computational prediction, knowledge
transfer between organism, and interactions aggregated from other (primary) databases
analysis [26].
2.7. HSP-Mediated Regulatory Network of miRNAs-mRNAs
The list of HSPs co-expressed miRNAs was retrieved using bcGenExMiner. Pearson’s
correlation coefficient was considered significant when p ≥ 0.4 and p ≤ −0.4. Positive
and negative HSPs co-expressed miRNAs were properly sorted to obtain two lists of up-
regulated miRNAs in a poor and in good prognosis. Within each list, only the miRNAs
recurring at least three times were selected for miRNAs-mRNAs network construction
using miRNet (www.mirnet.ca, accessed date 26 February 2021), an easy-to-use web-based
tool designed for creation, customization, visual exploration, and functional interpretation
of miRNA-target interaction networks [27]. miRNet was also used to predict miRNAs
acting on HSP-cluster associated with poor and good prognosis.
2.8. Identification of HSP Proteins and Isoforms in Breast Cancer Tissues
Two-dimensional (2D)-IPG electrophoresis was performed on 63 protein extracts from
breast cancer tissues obtained following surgical interventions during the years 2004–2010
at the “La Maddalena” Hospital of Palermo, as previously described [28–33]. Briefly, the
surgical samples homogenated overnight at 4 ◦C with RIPA buffer, were centrifugated, and
the supernatants were dialyzed against ultrapure distilled water, lyophilized and resus-
pended in ISOT buffer. Aliquots of 45 µg of total proteins were rehydrated in rehydration
Biology 2021, 10, 247 5 of 26
buffer containing 8 M urea, 2% CHAPS, 10 mM DTE, and 0.5% carrier ampholytes (Resolyte
3.5–10). The electrophoretic separation was performed on 18 cm long strips with a pH
range of 3–10. The strips were then equilibrated in a solution containing 50 mM Tris-HCl
pH 6.8, 6 M urea, 0.5% SDS, 30% Glycerol, 130 mM DTE and 135 mM Iodoacetamide and
then separated on 9–16% linear gradient polyacrylamide gels (SDS-PAGE), with a constant
current of 20 mA/gel, as previously described [34–36]. The gels were silver stained and
analyzed with the dedicated Image-Master 2D Platinum software. Proteins of interest were
excised from the gel and the identity was assigned by peptide mass fingerprinting using
the Voyager DE MALDI-TOF mass spectrometer as described [37–42]. The expression
level of protein spots was calculated as the volume of the spots (i.e., integration of optical
density over the spot area), relative to the sum of the volume of all spots on each gel (% Vol).
Measurements of relative expression levels of individual protein spots were normalized in
each proteomic map for actin content (N % V), as previously reported [43].
3. Results
We systematically analyzed by data mining 95 heat shock genes (and the protein
members that they encode), grouped into 6 sub-families (Table 1): (1) HSP 110 (HSPH)
with 2 genes; (2) HSP90 (HSPC) with 4 genes; (3) HSP70 (HSPA) with 15 genes; (4) HSP60
(Chaperonins) with 14 genes; (5) HSP20 (HSPB), with 11 genes; (6) HSP40 (DNAJ) with
49 genes.
Table 1. List of 95 HSP family members classified into 6 sub-families according to their molecular weight (HSP110, HSP90,
HSP70, HSP60, HSP40 and HSP20). For each HSP, the Gene name, Chromosomic localization, Affimetrix ID probe, Protein














HSPH1 13q12.3 235573_at Heat shock 105 kDa/110 kDa protein 1 Q92598 (HS105) 96,865
HYOU1 11q23.3 200825_s_at Hypoxia up-regulated protein 1 Q9Y4L1 (HYOU1) 111,335
HSP90
(HSPC)
HSP90AA1 14q32.31 214328_s_at Heat shock protein HSP 90-alpha P07900 (HS90A) 84,660
HSP90AB1 6Q21,1 200064_at Heat shock protein HSP 90-beta P08238 (HS90B) 83,264
HSP90B1 12q23.3 200599_s_at Endoplasmin P14625 (ENPL) 92,469
TRAP1 16P13.3 201391_at Heat shock protein 75 kDa,mitochondrial Q12931 (TRAP1) 80,110
HSP70
(HSPA)
HSPA1A 6p21.33 200799_at Heat shock 70 kDa protein 1A P0DMV8 (HS71A) 70,052
HSPA1B 6p21.33 202581_at Heat shock 70 kDa protein 1B P0DMV9 (HS71B) 70,052
HSPA1L 6p21.33 210189_at Heat shock 70 kDa protein 1-like P34931 (HS71L) 70,375
HSPA2 14q23.3 211538_s_at Heat shock-related 70 kDa protein 2 P54652 (HSP72) 70,021
HSPA4 5q31.1 208815_x_at Heat shock 70 kDa protein 4 P34932 (HSP74) 94,331
HSPA4L 4q28 205543_at Heat shock 70 kDa protein 4L O95757 (HS74L) 94,512
HSPA5 9q33.3 230031_at Endoplasmic reticulum chaperone BiP P11021 (BIP) 72,333
HSPA6 1q23.3 117_at Heat shock 70 kDa protein 6 P17066 (HSP76) 71,028
HSPA7 1q23.3 - Putative heat shock 70 kDa protein 7 P48741 (HSP77) 40,244
HSPA8 11q24.1 221891_x_at Heat shock cognate 71 kDa protein P11142 (HSP7C) 70,898
HSPA9 5q31.1 200690_at Stress-70 protein, mitochondrial P38646 (GRP75) 73,680
HSPA12A 10q25.3 214434_at Heat shock 70 kDa protein 12A O43301 (HS12A) 74,978
HSPA12B 20p13 229172_at Heat shock 70 kDa protein 12B Q96MM6 (HS12B) 75,688
HSPA13 21q11.2 202557_at Heat shock 70 kDa protein 13 P48723 (HSP13) 51,927




BBS10 12q21.2 219487_at Bardet-Biedl syndrome 10 protein Q8TAM1 (BBS10) 80,838
BBS12 4q27 229603_at Bardet-Biedl syndrome 12 protein Q6ZW61 (BBS12) 79,085
TCP1 6q25.3 222010_at T-complex protein 1 subunit alpha P17987 (TCPA) 60,344
CCT2 12q15 201947_s_at T-complex protein 1 subunit beta P78371 (TCPB) 57,488
CCT3 1q23 200910_at T-complex protein 1 subunit gamma P49368 (TCPG) 60,534
CCT4 2p15 200877_at T-complex protein 1 subunit delta P50991 (TCPD) 57,924
CCT5 5p15.2 229068_at T-complex protein 1 subunit epsilon P48643 (TCPE) 59,671
CCT6A 7p11.2 201326_at T-complex protein 1 subunit zeta P40227 (TCPZ) 58,024
CCT6B 17q12 206587_at T-complex protein 1 subunit zeta-2 Q92526 (TCPW) 57,821













CCT7 2p13.2 200812_at T-complex protein 1 subunit eta Q99832 (TCPH) 59,367
CCT8 21q22.11 200873_s_at T-complex protein 1 subunit theta P50990 (TCPQ) 59,621
HSPD1 2q33.1 200807_s_at 60 kDa heat shock protein,mitochondrial P10809 (CH60) 61,055
HSPE1 2q33.1 205133_s_at 10 kDa heat shock protein,mitochondrial P61604 (CH10) 10,932
MKKS 20p12 218138_at McKusick-Kaufman/Bardet-Biedlsyndromes putative chaperonin Q9NPJ1 (MKKS) 62,342
HSP40
(DNAJ)
DNAJA1 9p21.1 200881_s_at DnaJ homolog subfamily A member 1 P31689 (DNJA1) 44,868
DNAJA2 16q12.1 226994_at DnaJ homolog subfamily A member 2 O60884 (DNJA2) 45,746
DNAJA3 16p13.3 205963_s_at DnaJ homolog subfamily A member 3,mitochondrial Q96EY1 (DNJA3) 52,489
DNAJA4 15q25.1 225061_at DnaJ homolog subfamily A member 4 Q8WW22 (DNJA4) 44,798
DNAJB1 19p13.2 200666_s_at DnaJ homolog subfamily B member 1 P25685 (DNJB1) 38,044
DNAJB2 2q35 202500_at DnaJ homolog subfamily B member 2 P25686 (DNJB2) 35,580
DNAJB3 2q37.1 - DnaJ homolog subfamily B member 3 Q8WWF6 (DNJB3) 16,559
DNAJB4 1p31.1 203810_at DnaJ homolog subfamily B member 4 Q9UDY4 (DNJB4) 37,807
DNAJB5 9p13.1 212817_at DnaJ homolog subfamily B member 5 O75953 (DNJB5) 39,133
DNAJB6 7q36.3 209015_s_at DnaJ homolog subfamily B member 6 O75190 (DNJB6) 36,087
DNAJB7 22q13.2 1552675_at DnaJ homolog subfamily B member 7 Q7Z6W7 (DNJB7) 35,434
DNAJB8 3q21.3 237284_at DnaJ homolog subfamily B member 8 Q8NHS0 (DNJB8) 25,686
DNAJB9 7q31.1 202843_at DnaJ homolog subfamily B member 9 Q9UBS3 (DNJB9) 25,518
DNAJB11 3q27.3 223054_at DnaJ homolog subfamily B member 11 Q9UBS4 (DJB11) 40,514
DNAJB12 10q22.1 202866_at DnaJ homolog subfamily B member 12 Q9NXW2 (DJB12) 41,860
DNAJB13 11q13.4 230936_at DnaJ homolog subfamily B member 13 P59910 (DJB13) 36,118
DNAJB14 4q23 226399_at DnaJ homolog subfamily B member 14 Q8TBM8 (DJB14) 42,516
DNAJC1 10p12.31 218409_at DnaJ homolog subfamily C member 1 Q96KC8 (DNJC1) 63,883
DNAJC2 7q22.1 213097_s_at DnaJ homolog subfamily C member 2 Q99543 (DNJC2) 71,996
DNAJC3 13q32.1 225284_at DnaJ homolog subfamily C member 3 Q13217 (DNJC3) 57,580
DNAJC4 11q13.1 228622_s_at DnaJ homolog subfamily C member 4 Q9NNZ3 (DNJC4) 27,593
DNAJC5 20q13.33 224611_s_at DnaJ homolog subfamily C member 5 Q9H3Z4 (DNJC5) 22,149
DNAJC5B 8q13.1 232798_at DnaJ homolog subfamily C member 5B Q9UF47 (DNJ5B) 22,496
DNAJC5G 2p23.3 1552450_a_at DnaJ homolog subfamily C member5G Q8N7S2 (DNJ5G) 21,433
DNAJC6 1p31.3 204721_s_at Putative tyrosine-protein phosphataseauxilin O75061 (AUXI) 99,997
DNAJC7 17q21.2 202416_at DnaJ homolog subfamily C member 7 Q99615 (DNJC7) 56,441
DNAJC8 1p35.3 212490_at DnaJ homolog subfamily C member 8 O75937 (DNJC8) 29,842
DNAJC9 10q22.2 213088_s_at DnaJ homolog subfamily C member 9 Q8WXX5 (DNJC9) 29,910
DNAJC10 2q32.1 229588_at DnaJ homolog subfamily C member 10 Q8IXB1 (DJC10) 91,080
DNAJC11 1p36.31 215792_s_at DnaJ homolog subfamily C member 11 Q9NVH1 (DJC11) 63,278
DNAJC12 10q21.3 223722_at DnaJ homolog subfamily C member 12 Q9UKB3 (DJC12) 23,415
DNAJC13 3q22.1 212467_at DnaJ homolog subfamily C member 13 O75165 (DJC13) 254,415
DNAJC14 12q13.2 223420_at DnaJ homolog subfamily C member 14 Q6Y2X3 (DJC14) 78,569
DNAJC15 13q14.11 227808_at DnaJ homolog subfamily C member 15 Q9Y5T4 (DJC15) 16,383
DNAJC16 1p36.21 212911_at DnaJ homolog subfamily C member 16 Q9Y2G8 (DJC16) 90,591
DNAJC17 15q15.1 219861_at DnaJ homolog subfamily C member 17 Q9NVM6 (DJC17) 34,687
DNAJC18 5q31.2 238115_at DnaJ homolog subfamily C member 18 Q9H819 (DJC18) 41,551
DNAJC19 3q26.33 225358_at Mitochondrial import inner membranetranslocase subunit TIM14 Q96DA6 (TIM14) 12,499
HSCB 22q12.1 223647_x_at Iron-sulfur cluster co-chaperoneprotein HscB Q8IWL3 (HSC20) 27,422
DNAJC21 5p13.1 230893_at DnaJ homolog subfamily C member 21 Q5F1R6 (DJC21) 62,028
DNAJC22 12q13.12 220441_at DnaJ homolog subfamily C member 22 Q8N4W6 (DJC22) 38,086
SEC63 6q21 229969_at Translocation protein SEC63 homolog Q9UGP8 (SEC63) 87,997
DNAJC24 11p13 213853_at DnaJ homolog subfamily C member 24 Q6P3W2 (DJC24) 17,139
DNAJC25 9q31.3 226859_at DnaJ homolog subfamily C member 25 Q9H1X3 (DJC25) 42,404
GAK 4p16.3 40225_at Cyclin-G-associated kinase O14976 (GAK) 143,191
DNAJC27 2p23.3 227859_at DnaJ homolog subfamily C member 27 Q9NZQ0 (DJC27) 30,855
DNAJC28 21q22.11 220372_at DnaJ homolog subfamily C member 28 Q9NX36 (DJC28) 45,806
SACS 13q12.12 213262_at Sacsin Q9NZJ4 (SACS) 521,126
DNAJC30 7q11.23 223367_at DnaJ homolog subfamily C member30, mitochondrial Q96LL9 (DJC30) 25,961















HSPB1 7q11.23 201841_s_at Heat shock protein beta-1 P04792 (HSPB1) 22,783
HSPB2 11q23.1 205824_at Heat shock protein beta-2 Q16082 (HSPB2) 20,233
HSPB3 5q11.2 206375_s_at Heat shock protein beta-3 Q12988 (HSPB3) 16,966
CRYAA 21q22.3 210199_at Alpha-crystallin A chain P02489 (CRYAA) 19,909
CRYAB 11q22.3 209283_at Alpha-crystallin B chain P02511 (CRYAB) 20,159
HSPB6 19q13.12 226304_at Heat shock protein beta-6 O14558 (HSPB6) 17,136
HSPB7 1p36.13 218934_s_at Heat shock protein beta-7 Q9UBY9 (HSPB7) 18,611
HSPB8 12q24.23 221667_s_at Heat shock protein beta-8 Q9UJY1 (HSPB8) 21,604
HSPB9 17q21.2 230510_at Heat shock protein beta-9 Q9BQS6 (HSPB9) 17,486
OFD1 8q22.3 203569_s_at Oral-facial-digital syndrome 1 protein O75665 (OFD1) 116,671
HSPB11 1p32 215691_x_at Intraflagellar transport protein 25homolog Q9Y547 (IFT25) 16,297
3.1. Gene Expression Analysis of HSP Family Members between Normal and Cancer Tissues
The expression profiles of HSP family members in breast cancer were determined
using UALCAN database. Among the 95 HSP members, 76 were significantly deregulated
in cancer tissues when compared to the corresponding normal tissues. In particular,
50 HSPs, were found up-regulated (Figure 1A, Table 2) while 26 HSPs, were found down-
regulated in breast cancer than normal tissues (Figure 1B, Table 2). Interestingly, the
number of transcripts, per million, was spanning between 0.07 for DNAJA5G and 3500
for HSPB1 and CRYAB, suggesting that some members are expressed at very low levels
(HSPA1L, HSPB9, DNAJB7, DNAJ5B, DNAJC6, DNAJC27, and DNAJC28) while others are
expressed at high levels (HSPA1A, HSPA8, HSPB6, HSP90AA1, HSP90AB1, and HSP90B1).
Next, Oncomine meta-analysis was employed to assess the comprehensive expression of
HSP members across 20 cancer types (Figure S1). The database compared the HSPs gene
expression levels in cancer versus normal samples across a wide variety of datasets in
different cancer types. A total of 1460 analyses showed a significant statistical difference for
mRNA expression in cancer versus normal samples (the selected thresholds for the analyses
were: p-value: 1 × 10−4; fold change: 2; gene rank: top 10%; data type: mRNA; sample
type: clinical specimens). Overlapping results were recorded between UALCAN and
Oncomine platforms except for HSPA1A, HSPA1L, HSPA2, DNAJA4, DNAJB2, DNAJC4,
DNAJC11, DNAJC21 and GAK found up-regulated in breast cancer but collectively down-
regulated in the other tumors, and DNAJC8, DNAJC24, SACS and HSPB6 down-regulated
in breast cancer and collectively up-regulated in other tumors. The obtained results clearly
indicated that the HSP members are involved in carcinogenesis, acting both as oncogenes
or suppressor genes, and suggested that some of them could exert specific roles in different
cancer types. Moreover, a high agreement was obtained using different bioinformatics
platforms, supporting the robustness of the results.
Biology 2021, 10, 247 8 of 26
Figure 1. Cont.
Biology 2021, 10, 247 9 of 26
Figure 1. Gene expression analysis of HSP members between normal and breast cancer samples analyzed by UALCAN
database. (A) Box plots of HSP genes up-regulated in BC compared to normal tissues. (B) Box plots of HSP genes
down-regulated in BC compared to normal tissues. p < 0.01 was considered significant.























HSPH1 1.62 × 10−12 HSPB1 1.62 × 10−12 HSPA4L 1.63 × 10−5
HYOU1 <1 × 10−12 HSPB11 1.62 × 10−12 HSPA12A 2.24 × 10−12
HSP90AA1 1.62 × 10−12 DNAJA1 <1 × 10−12 HSPA12B 1.62 × 10−12
HSP90AB1 1.62 × 10−12 DNAJA3 <1 × 10−12 BBS10 1.1 × 10−16
HSP90B1 1.62 × 10−12 DNAJA4 1.62 × 10−12 BBS12 1.62 × 10−12
TRAP1 1.62 × 10−12 DNAJB2 1.7 × 10−12 TCP1 3.19 × 10−9
HSPA1A 5.62 × 10−4 DNAJB6 5.59 × 10−10 CCT6B 4.61 × 10−10
HSPA1L 8.43 × 10−5 DNAJB11 1.62 × 10−12 HSPB2 <1 × 10−12
HSPA2 1.69 × 10−12 DNAJC1 1.11 × 10−16 CRYAB 1.62 × 10−12
HSPA4 <1 × 10−12 DNAJC2 1.62 × 10−12 HSPB6 <1 × 10−12
HSPA5 1.62 × 10−12 DNAJC4 3.87 × 10−7 HSPB7 3.76 × 10−11



























HSPA6 2.87 × 10−7 DNAJC5 <1 × 10−12 HSPB9 3.89 × 10−3
HSPA8 1.62 × 10−12 DNAJC5B 1.05 × 10−9 DNAJA2 4.36 × 10−5
HSPA9 <1 × 10−12 DNAJC7 1.62 × 10−12 DNAJB4 1.62 × 10−12
HSPA13 1.62 × 10−12 DNAJC9 <1 × 10−12 DNAJB7 2.01 × 10−5
HSPA14 <1 × 10−12 DNAJC10 1.11 × 10−16 DNAJB13 2.13 × 10−6
CCT2 1.62 × 10−12 DNAJC11 2.97 × 10−9 DNAJB14 1.62 × 10−3
CCT3 <1 × 10−12 DNAJC12 1.62 × 10−12 DNAJC5G 1.21 × 10−4
CCT4 1.98 × 10−4 DNAJC14 1.62 × 10−12 DNAJC6 1.64 × 10−12
CCT5 <1 × 10−12 DNAJC17 8.1 × 10−5 DNAJC8 3.4 × 10−8
CCT6A 1.11 × 10−16 DNAJC19 <1 × 10−12 DNAJC13 3.5 × 10−3
CCT7 <1 × 10−12 DNAJC21 1.64 × 10−13 DNAJC18 <1 × 10−12
CCT8 1.62 × 10−12 DNAJC22 1.62 × 10−12 DNAJC24 7.52 × 10−5
HSPD1 1.62 × 10−12 GAK 1.62 × 10−12 DNAJC27 1.62 × 10−12
HSPE1 <1 × 10−12 DNAJC30 1.27 × 10−7 DNAJC28 8.74 × 10−12
SACS <1 × 10−12
3.2. Genetic and Epigenetic Alterations of HSP Members
It is well-recognized that the expression levels of selected genes could depend on ge-
netic (amplifications or deletions) and epigenetic (promotor methylation status) alterations.
To verify whether the deregulated expression of HSP members in breast cancer could be
caused by one or a combination of these factors, the genetic mutations of HSP members,
in a cohort of breast cancer patients using cBioPortal web, were analyzed. The mutation
rate was higher for the HSP members up-regulated in BC (Figure 2A), spanning from 0.4%
to 12%. Among these, TRAP1, HSPA6, CCT2, CCT3, DNAJA3, DNAJC5, DNAJC5B and
DNAJC19 showed a percentage of alterations higher than 3%. A lower mutation rate was
recorded for HSP members down-regulated in BC (Figure 2B), spanning from 0.2% to 4%.
Among these, only DNAJB13 showed a percentage of alteration higher than 3%. Concern-
ing the type of HSPs alteration, amplification was the major one, followed by deletion.
A very low percentage of missense mutations was detected in all the analyzed samples.
Promoter methylation status was analyzed from TCGA data through UALCAN database.
Among the differentially expressed HSPs, 26 over 50 up-regulated (Figure 3A) and 17 over
26 down-regulated (Figure 3B), showed statistical differences in promoter methylation
status between normal and breast cancer samples. Different beta value cut-off indicates
hyper-methylation [beta value: 0.7–0.5] or hypo-methylation [beta-value: 0.3–0.25]. Inter-
estingly, based on beta values, 23/26 HSPs were found with the hypo-methylated promoter
and 9/17 HSPs were validated with the hyper-methylated promoter. According to expres-
sion pattern analysis among the HSPs up-regulated in BC, 15/26 showed lower promoter
methylation while among the HSPs down-regulated in BC, 10/17 showed higher promoter
methylation in tumor samples compared with normal samples. These data suggested that
the deregulated HSPs gene expression associated with BC may be partly due to genetic
and epigenetic alterations.
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Figure 2. Analysis of genetic alterations in HSP members differentially expressed in BC. The percentage of alterations in
HSP genes was extracted by using the OncoPrint tool of cBioPortal containing sequencing data of 2509 patients. Red and
blue represent amplification, and deep deletion, respectively, green and grey represent missense and truncating mutations.
Asterisk * indicates the corresponding HSP members showing a percentage of alteration higher than 3%. Histograms
showing the percentage of genetic alterations of HSP genes up-regulated (A), and down-regulated (B) in BC.
3.3. HSPs Expression and Clinical Outcome
To analyze the prognostic value of the HSP members, Kaplan Meier-plotter database
restricted to BC was searched. For each HSP gene (using the Affimetrix ID probe listed
in Table 1), the survival outcomes were evaluated as Relapse Free Survival (RSF), Distant
Metastasis Free Survival (DMFS), and Overall Survival (OS), (Table S1). Patients were
divided into two groups (high and low) based on the expression levels of individual HSPs
by selecting the best cut-off. In this case, the software computed all possible cut-off values
between the lower and the upper quartiles and the best performing threshold was used as
the cut-off value. HSPs expression levels were considered as significantly associated with
prognosis when all survival outcomes (RSF, DMSF, and OS) were coherently significant
(Table 3, Figure S2). The increased expression levels of 21 HSPs were significantly associated
with a worse prognosis, whereas high transcriptional levels of 13 HSPs favored a good
prognosis. Among these, only HSPA1B, DNAJB1, DNAJB8, DNAJB12, and DNAJC16 were
not differentially expressed in BC, and thus, not further considered. Interestingly, when
the survival analyses were re-evaluated, including the panel of worse prognosis-associated
HSPs, better prognostic values than the individual ones were obtained (Figure 4A). Similar
results (Figure 4B) were obtained including the panel of good prognosis-associated HSPs.
These results revealed that collectively, the selected clusters of 19 HSPs and 10 HSPs
could be represent robust biomarkers for poor and good prognosis in breast cancer, than
individual members.
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Figure 3. Analysis of promoter methylation status in HSP members differentially expressed in BC. For each HSP member
the levels of promoter methylation between normal and breast cancer were retrieved from UALCAN database. Beta value
cut-off indicates hyper-methylation [beta value: 0.7–0.5] or hypo-methylation [beta-value: 0.3–0.25]. HSP members with
hyper-methylated promoters are marked in green; HSP members with hypo-methylated promoters are marked in black.
Box plots showing the promoter methylation status between normal and breast primary tumors in HSPs up-regulated (A)
and down-regulated in BC (B). p < 0.01 was considered significant.
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Table 3. List of HSP members significantly associated with clinical outcome, including Relapse Free Survival (RFS), Overall
Survival (OS), and Distant Metastasis Free Survival (DMFS), evaluated by KM Plotter database. The Log Rank value was
marked in red when higher expression of selected HSP was associated with poor prognosis and in the black when higher
expression of selected HSP was associated with a good prognosis. The probe expression value cut-off for each analysis is
also reported.
Gene RFS OS DMFS
Used Cut-Off Logrank P Used Cut-Off Logrank P Used Cut-Off Logrank P
HSP90AA1 20,364 <1 × 10−16 23,504 5.7 × 10−7 20,054 3.8 × 10−4
HSPA1A 9077 9.4 × 10−5 13,346 2.5 × 10−3 9089 8 × 10−4
HSPA1B 2046 8.3 × 10−4 1254 9.2 × 10−4 1829 6.8 × 10−3
HSPA8 14,679 <1 × 10−16 14,679 5.5 × 10−3 14,018 1.7 × 10−2
HSPA14 490 1.7 × 10−5 477 1.7 × 10−4 490 2.2 × 10−3
TCP1 601 7.4 × 10−11 676 1.5 × 10−7 562 1.2 × 10−4
CCT2 5366 <1 × 10−16 5370 2.7 × 10−8 4520 2 × 10−7
CCT3 4554 2.9 × 10−15 4619 1.2 × 10−2 4735 1.9 × 10−3
CCT4 5934 1.10 × 10−11 5587 2.9 × 10−2 6778 3.32 × 10−2
CCT6A 1676 <1 × 10−16 1667 2 × 10−8 1678 7.6 × 10−6
CCT7 2498 <1 × 10−16 2394 5 × 10−4 2466 1.4 × 10−3
CCT8 5676 <1 × 10−16 4599 5.5 × 10−5 3613 1.1 × 10−4
HSPD1 11,874 <1 × 10−16 11,640 7.7 × 10−7 10,253 5.6 × 10−6
DNAJA1 5070 2 × 10−14 4099 2.7 × 10−4 4939 1 × 10−4
DNAJB1 2284 8.7 × 10−4 2312 4 × 10−2 2369 1.1 × 10−2
DNAJB11 1771 1.3 × 10−9 2300 4.20 × 10−2 1910 2.5 × 10−4
DNAJC2 1153 2.5 × 10−16 781 1.7 × 10−3 1049 9.1 × 10−4
DNAJC5 768 3.9 × 10−2 748 1.8 × 10−3 591 4.8 × 10−2
DNAJC9 1494 <1 × 10−16 1296 1.5 × 10−7 1328 1.3 × 10−6
DNAJC17 128 1.6 × 10−2 128 2 × 10−2 163 3.6 × 10−3
HSPB1 9981 2.4 × 10−12 5940 3.5 × 10−4 7584 1.3 × 10−7
HSPA2 536 2.2 × 10−10 624 5.8 × 10−5 563 1.7 × 10−6
BBS12 186 1 × 10−10 185 3.8 × 10−4 187 4.7 × 10−3
DNAJB8 26 4 × 10−5 23 3.7 × 10−2 24 7.4 × 10−3
DNAJB12 644 6.4 × 10−10 644 1.5 × 10−2 879 2.5 × 10−2
DNAJB14 757 5.5 × 10−8 1147 1.2 × 10−4 1164 2.7 × 10−2
DNAJC4 487 3.3 × 10−10 489 9 × 10−3 445 2.9 × 10−3
DNAJC5G 54 1.3 × 10−8 27 2.3 × 10−3 54 1.5 × 10−2
DNAJC10 171 5.3 × 10−12 202 9.6 × 10−3 187 4.3 × 10−2
DNAJC12 92 1.4 × 10−7 127 5.3 × 10−4 92 1.8 × 10−5
DNAJC14 433 3.8 × 10−10 393 5.2 × 10−3 529 1.5 × 10−2
DNAJC16 402 8.3 × 10−11 361 5.8 × 10−9 402 4.7 × 10−8
DNAJC19 562 1.4 × 10−10 578 1.6 × 10−7 578 3.1 × 10−7
CRYAB 575 1.7 × 10−2 522 3.8 × 10−3 848 3.2 × 10−2
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Figure 4. Survival curves of HSP members significantly associated with prognosis. The analysis is shown for Relapse Free
Survival (RFS) Overall Survival (OS) and Distant Metastasis Free Survival (DMFS) using the Kaplan-Meier Plotter database.
Patients were divided into two groups by using the best cut-off of probe expression. Survival curves of HSP-cluster
associated with poor (A) and good (B) prognosis.
3.4. Relationship between HSP Members and Clinical-Pathological Parameters
The relationship between the expression levels of HSP-clusters differentially asso-
ciated with prognosis and current clinical-pathological parameters was assessed using
bcGeneXMiner and GOBO databases (Table 4). Clinical parameters included immuno-
cytochemical expression of estrogen receptor (ER), progesterone receptor (ER), human
epidermal growth receptor 2 (HER), lymph node (N) metastases, and grading (G1-G2-G3).
The HSP-cluster associated with poor prognosis showed significant correlations with ER-
/PR-, HER+, N+, and G3 tumors, which clinically identify more aggressive tumors. On
the contrary, for the HSP-cluster associated with a good prognosis, an inverse trend of
correlation with ER+/PR+, HER- N- and G1 tumors was found. Accordingly, it is well
known that HER-, N- and G1 tumors are less aggressive. The obtained results confirm that
the identified clusters can group patients with homogeneous clinical characteristics and
underline their robustness in predicting prognosis in subgroups of patients.
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Table 4. Relationship between HSPs mRNA expression in BC and clinical-pathological parameters, including estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER) status, lymph node (N) involve-
ment, and grading (G1–G2–G3). Data were retrieved for each HSP using bcGeneXMiner and the grading was assessed
using GOBO database. p < 0.05 was considered significant (p < 0.05 *, p < 0.01 **, p < 0.001 ***).
Gene
Name ER+/PR+ ER-/PR- HER+ HER- N+ N- G1 G2 G3
HSPA1A <0.0001 *** - - 0.0315 * - - -
HSPA8 <0.0001 *** 0.0022 ** 0.0002 *** - - -
HSPA14 <0.0001 *** <0.0001 *** 0.0134 ** <0.0001 ***
HSPB1 <0.0001 *** - - <0.0001 *** <0.0001 ***
HSP90AA1 <0.0001 *** <0.0001 *** <0.0001 *** <0.0001 ***
TCP1 <0.0001 *** <0.0001 *** 0.0175 ** <0.0001 ***
CCT2 - - 0.0066 ** 0.0003 *** <0.0001 ***
CCT3 <0.0001 *** 0.0001 *** 0.0025 ** <0.0001 ***
CCT4 <0.0001 *** - - - - <0.0001 ***
CCT6A <0.0001 *** <0.0001 *** <0.0001 *** <0.0001 ***
CCT7 <0.0001 *** - - <0.0001 *** <0.0001 ***
CCT8 <0.0001 *** - - - - <0.0001 ***
HSPD1 <0.0001 *** <0.0001 *** <0.0001 *** <0.0001 ***
DNAJA1 <0.0001 *** 0.0091 ** <0.0001 *** <0.0001 ***
DNAJB11 <0.0001 *** <0.0001 *** - - - - -
DNAJC2 <0.0001 *** - - 0.0002 *** <0.0001 ***
DNAJC5 <0.0001 *** <0.0001 *** 0.0050 ** - - -
DNAJC9 <0.0001 *** 0.0042 ** 0.0213 * <0.0001 ***
DNAJC17 <0.0001 *** - - - - <0.0001 ***
HSPA2 <0.0001 *** <0.0001 *** - - <0.0001 ***
BBS12 <0.0001 *** <0.0001 *** 0.0404 * - - -
DNAJB14 <0.0001 *** - - - - <0.0001 ***
DNAJC4 0.01 * 0.0057 ** <0.0001 *** <0.0001 ***
DNAJC5G - - - - - - - - -
DNAJC10 - - <0.0001 *** - - 0.00011 ***
DNAJC12 <0.0001 *** <0.0001 *** - - <0.0001 ***
DNAJC14 <0.0001 *** 0.0003 *** - - - - -
DNAJC19 <0.0001 *** <0.0001 *** - - - - -
CRYAB <0.0001 *** <0.0001 *** - - - - -
3.5. HSPs-Gene Co-Expression Networks
To unveil the mechanisms by which HSPs deregulation affect breast cancer develop-
ment and influence prognosis, we identified the predicted genes that are transcriptionally
co-expressed with individual HSPs via computational analysis. The co-expressed genes
for the HSP-cluster that are significantly associated with a poor and good prognosis were
queried to GOBO, UALCAN, and bc-GenExMiner database, respectively, using a Pearson
correlation score of ≥ 0.4. The lists of the derived positive and negative HSPs co-expressed
genes (Table S2), were appropriately sorted to obtain up-regulated genes in poor prognosis
and up-regulated genes in good prognosis. Functional enrichments in the HSP-regulated
networks (biological pathways) were highlighted by using the Fun Rich tool. Although
each HSP was significantly associated with different genes in different databases, they were
implicated in similar biological functions. Overall, biological processes were included in
the mitotic cell cycle, DNA replication and cell cycle checkpoint for the co-expressed HSP
genes up-regulated in poor prognosis, independently from the used database (Figure 5A,
Figure S3A), suggesting that these HSPs-regulated biological processes might play a signifi-
cant role in the initiation and progression of breast cancer. Less robust results were obtained
for the co-expressed HSP genes up-regulated in good prognosis (Figure 5B, Figure S3B):
the biological processes in which these genes are involved were Epithelial to Mesenchymal
Transition (ETM) for the gene list derived from GOBO and bc-GenExMiner, and receptor
signaling network (PAR-1, c-MET, VEGFR1, VEGFR2, HER2) for the gene list derived from
UALCAN. Interestingly, when the list of common genes from the three bioinformatics plat-
forms (Figure 5C,D) was used to find functional protein-protein interactions by using the
STRING analysis tool (Figure 5E,F), a significant network, involved in cell cycle and DNA
replication, was obtained for the co-expressed HSP genes up-regulated in poor prognosis.
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Again, the protein-protein interaction network derived from the co-expressed HSP genes
up-regulated in good prognosis, was less robust and affected the Estrogen-dependent gene
expression. Collectively, the pathway analysis of HSP co-expressed genes showed a specific
signature for poor prognosis, affecting cell cycle and DNA replication.
Figure 5. Enrichment pathway analysis of HSPs co-expressed genes significantly correlated with prognosis. Significantly
enriched biological pathways were ranked by p-value using the FunRich 3.0 software. (A,B) The top six biological pathways
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in which the HSPs co-expressed genes up-regulated in poor and good prognosis, derived from GOBO, were significantly
involved. (C,D) Venn diagrams of overlapping HSPs co-expressed genes up-regulated in poor and good prognosis, derived
from GOBO, UALCAN, and bc-GenExMiner. (E,F) Protein-protein interaction network of the common HSPs co-expressed
genes derived from the three cross-platforms GOBO, UALCAN and bc-GenExMiner using STRING database. The network
was performed with medium confidence (combined score > 0.4) and disconnected nodes were deleted.
3.6. Regulatory Network Analysis of HSPs-miRNA-mRNA
To further explore the molecular mechanisms responsible for HSPs effects on BC, we
analyzed the networks of HSPs co-expressed miRNAs generated by the bc-GenExMiner
database. Positive and negative HSPs co-expressed miRNAs were properly sorted to obtain
two lists of up-regulated miRNAs in poor and in good prognosis. Only the miRNAs
repeated at least three times were selected for miRNA-mRNA network construction using
miRNet. A total of 14 miRNAs were clustered within the miRNAs network up-regulated
in poor prognosis (Table 5). Interestingly, the target genes were involved in the cell
cycle (Figure S4A). A total of 20 miRNAs were clustered within the miRNAs network
up-regulated in good prognosis (Table 5). The target genes were implicated in the negative
regulation of DNA-dependent transcription (Figure S4B). Interestingly, among the HSPs co-
expressed miRNAs up-regulated in poor prognosis 5 miRNAs (hsa-mir-320b-2, hsa-mir-545,
hsa-mir-651, hsa-mir-570, hsa-mir-643) were significantly up-regulated in breast cancer than
normal tissues, as verified by using UALCAN, while among the HSPs associated miRNAs
up-regulated in good prognosis, 10 miRNAs (hsa-mir-143, hsa-mir-196b, hsa-mir-145, hsa-
mir-150, hsa-mir-1228, hsa-mir-1910, hsa-mir-1247, hsa-mir-411, hsa-mir-370, hsa-mir-770)
were significantly down-regulated in BC compared to normal tissues. As the mRNAs-
miRNAs network was created considering the HSPs clusters associated with prognosis, a
greater interconnection mRNAs-miRNAs was recorded for the cluster associated with poor
prognosis (Figure S4C), compared to the network obtained for HSPs-cluster associated
with good prognosis (Figure S4D). As expected, collectively they were involved in protein
folding. Several miRNAs, selected as key components of the networks, showed significant
differences between breast cancer than normal tissues. In particular, 12 of them were
up-regulated in breast cancer tissues, while 6 of them were down-regulated in breast
cancer. These results, for the first time, indicated that the HSPs deregulation in BC affected
epigenetic networks involving also several microRNAs, pointing that the complex network
triggered by HSPs deregulation provides a distinctive molecular portrait of each tumor.
Table 5. List of the hubs miRNAs involved in the HSPs-miRNAs-mRNAs network. The red bolded miRNAs were
significantly up-regulated in breast cancer than normal tissues; the black bolded miRNAs were significantly down-regulated
in breast cancer than normal tissues. A p-value < 0.01 was regarded as significant.
HSPs Co-Expressed miRNAs
Up-Regulated in Poor Prognosis
HSPs Co-Expressed miRNAs
Up-Regulated in Good Prognosis
hsa-mir-320b-2 7.13 × 10−7 hsa-mir-23a -
hsa-mir-545 4.38 × 10−12 hsa-mir-143 1.62 × 10−12
hsa-mir-941-2 - hsa-mir-185 1.42 × 10−4
hsa-mir-651 <1 × 10−12 hsa-mir-196b 5.07 × 10−2
hsa-mir-383 5.48 × 10−7 hsa-mir-145 <1 × 10−12
hsa-mir-1914 - hsa-mir-150 4.4 × 10−11
hsa-mir-570 5.56 × 10−5 hsa-mir-1228 3.04 × 10−2
hsa-mir-647 - hsa-mir-1910 4.10 × 10−5
hsa-mir-1227 - hsa-mir-450a-1 -
hsa-mir-593 - hsa-mir-548i-1 -
hsa-mir-300 - hsa-mir-1247 1.24 × 10−14
hsa-mir-643 9.17 × 10−11 hsa-mir-411 2.00 × 10−5
hsa-mir-626 - hsa-mir-1299 -
hsa-mir-1289-1 - hsa-mir-370 4.12 × 10−5
hsa-mir-544a -
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Table 5. Cont.
HSPs-miRNAs network
associated with poor prognosis
hsa-mir-1200 -
hsa-mir-3654 8.15 × 10−9
hsa-mir-16-5p - hsa-mir-770 6.09 × 10−05
hsa-mir-23b-3p - hsa-mir-555 -
hsa-mir-15a-5p 3.88 × 10−15 hsa-mir-604 -
hsa-mir-34a-5p -
hsa-mir-1-3p - HSPs-miRNAs network associated with good prognosis
hsa-mir-103a-3p <1 × 10−12
hsa-mir-148a-3p 6.5 × 10−13 hsa-mir-16-5p -
hsa-mir-424-5p - hsa-mir-155-5p 1.62 × 10−12
hsa-mir-107 2.4 × 10−11 hsa-mir-146a-5p 5.77 × 10−05
hsa-mir-155-5p 1.62 × 10−12 hsa-mir-124-3p -
hsa-mir-497-5p <1 × 10−12 hsa-mir-1-3p -
hsa-mir-181a-5p 8.31 × 10−03 hsa-mir-182-5p 1.62 × 10−12
hsa-mir-21-3p <1 × 10−12 hsa-mir-191-5p <1 × 10−12
hsa-mir-15b-3p 6.96 × 10−10 hsa-mir-17-5p <1 × 10−12
hsa-mir-186-5p 0.00446 hsa-mir-23b-3p -
hsa-mir-195-5p <1 × 10−12 hsa-mir-34a-5p -
hsa-mir-141-5p 1.62 × 10−12 hsa-mir-15a-5p 3.88 × 10−15
hsa-mir-29a-3p 1.96 × 10−12 hsa-mir-20a-5p 1.1 × 10−11
hsa-mir-197-3p - hsa-mir-195-5p <1 × 10−12
hsa-mir-302c-3p -
3.7. Proteomics Expression of HSP Members and Prognostic Significance
Complementing the transcriptomics results with proteomics ones allows studying
globally the HSPs-network within cancer cells and is also necessary to validate the ex-
istence of different protein isoforms as well as the exact localization of proteins, tightly
linked to their function. The prognostic value of HSPs protein expression, evaluated
by immunohistochemistry (IHC) staining, was retrieved using The Human Protein Atlas
(HPA) database (Figure 6A). High expression levels of 5 HSP members (HSPA9, HSP90AA1,
TCP1, CCT4 and CCT6A) were significant associated with shorter overall survival, while a
high expression level of HSPA2 was associated with a good prognosis. Moreover, taking
advantage of our previous proteomic data, we performed a comprehensive screening of
protein spots, in different proteomic maps, and collectively the following HSP protein
members were identified: HYOU1 (HYOU1), HSP90AA1 (HS90A), HSP90AB (HS90B),
HSP90B1 (ENPL), HSPA1A (HS71A), HSPA4 (HSP74, 2 isoforms), HSPA5 (BIP), HSPA8
(HSP7C, 4 isoforms), HSPA9 (GRP75), HSPD1 (CH60, 4 isoforms), TCP1 (TCPA), CCT2
(TCPB), CCT3 (TCPG), CCT5 (TCPE), CCT6A (TCPZ), HSPB1 (HSP27, 7 isoforms), HSPE1
(CH10, 2 isoforms). Figure 6B shows a representative proteomic map of a breast surgical
tissue silver-stained, with cropped windows where the 17 identified HSPs proteins and 14
isoforms are marked with labels corresponding to the gene name. The protein identity was
assessed by Maldi-Tof (Table S3). Different isoforms of the same protein were labeled by
alphabetic letters starting from the more acidic one. Several HSP proteins and isoforms
showed high variability of expression between analyzed patients (Figure 6C), suggest-
ing that different proteins and isoforms should be used for patient stratification. Finally,
the immunohistochemical analysis using the HPA database gives us the possibility to
define HSPs protein localization in different compartments at a single-cell and subcellular
level and also provided important spatial information in the context of neighboring cells.
Figure 6D reports immunohistochemical staining of BC tumors showing weak, moderate
and strong expression of selected HSPs, based on the major number of identified isoforms
in proteomics maps. Interestingly, antibody immunoreactivity was observed in several
cellular compartments, such as cytoplasm, plasma membrane, and nucleus. Collectively,
our proteomic data on HSPs expression and prognostic value are in line with genomic data.
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Although, proteomic investigations showed a more complex scenario in which different
HSP-isoforms can operate within the cancer cells, creating new functional arrangements,
difficult to predict based on gene expression. In the hope for the clinical use of HSP-clusters,
both the gene and protein expression levels should be taken into consideration, for a more
accurate prognosis.
Figure 6. Proteomic expression of HSP members and prognostic significance. (A) Survival analysis of HSPs protein
expression evaluated by immunohistochemistry (IHC) staining, using The Human Protein Atlas (HPA) database. The
database was queried for each HSP member, and only significant analyses were reported; (B) Representative proteomic map
of a breast cancer tissue. The 2-D separation was performed on IPG gel strips (18 cm, 3.0–10 NL) followed by the SDS-PAGE
on a vertical linear-gradient slab gel (9–16%T). HSP protein members identified by Maldi-Tof spectrometry are marked
with the Gene name. When present, different isoforms of the same protein were jointly labeled; (C) Quantitative analysis of
HSP proteins, given as box-plot graph, in breast cancer tissues. Quantification was deduced by the 2D gels, analyzed by
Image-Master software. In the ordinate are the values of N%V; (D) Representative IHC images for individual HSP proteins
(HSPB1, HSPD1, and HSPA8) in breast cancer tissues showing weak, moderate and strong staining, respectively retrieved
by the HPA database. The antibody immune reactivity was observed in several cell compartments, such as cytoplasm,
plasma membrane as well as in nucleus.
Biology 2021, 10, 247 20 of 26
4. Discussion
HSPs are a ubiquitous and highly conserved protein class, essential for cell protection
from a wide range of harmful conditions, including heat shock, oxidative stress, inflam-
mation, and proteotoxic stress (a specific form of deleterious stress causing increased
levels of misfolded proteins). However, when the cells reach the limit of stress tolerance,
they activate apoptosis or autophagy. HSPs play critical roles in inhibiting pro-apoptotic
molecules through the modulation of several signaling cascades such as JNK, AKT, and
NF-κB [44]. Several HSP members are closely associated with the onset and progression
of several human cancer types [45–49], but the expression pattern and potential roles of
HSPs in breast cancer, as well as their underlying regulatory mechanisms, remain poorly
investigated. Only two recent studies investigated the prognostic significance of HSP
members in BC, exclusively limited to the transcriptomic analysis [50,51]. Here, for the
first time, we performed an integrated multi-omics analysis to assess the prognostic value
and the functional implications of HSPs deregulation in BC. Using UALCAN database, we
found that collectively HSP family members were deregulated in BC. In particular, 50 HSPs
members were significantly up-regulated in cancer compared to normal tissues, while
26 HSPs members were down-regulated. These results indicated that HSPs could act both
as oncogenes or tumor suppressor genes. Moreover, the Oncomine analysis of HSPs dereg-
ulation in different cancer types showed that HSPs exert both, pro- and anti-tumorigenic
actions depending on the tumor type.
HSP members are coded by distinct chromosomal loci that are not clustered. The
molecular basis of HSPs deregulation in BC has not been well-studied and may have
multiple molecular etiologies. For example, associated with genetic alterations and/or
epigenetic modifications. Collectively, we showed that the mutation rate (amplification
followed by deletion) was higher in HSP members up-regulated in BC, while a lower mu-
tation rate was detected in HSP members down-regulated in BC. Besides, HSPs promoter
regions were found to be commonly hypo-methylated in HSP members up-regulated in
BC, while a general tendency to hyper-methylated promoters was detected in HSP mem-
bers down-regulated in BC. In alignment with our results, the CpG island located in the
promoter regions of the DNAJC10 gene was found to be frequently hypo-methylated in
breast cell lines [52]. We speculate that genetic alterations and epigenetic deregulations
could in part explain the deregulation of HSPs in BC. Other mechanisms responsible for
HSPs deregulation are: (1) The heat shock factor (HSF) family that ensures prompt tran-
scriptional activation of HSP members under stress and equally precipitous switch-off
after recovery [53]; (2) the genetic changes associated with tumor progression, producing
over-expressed onco-proteins, mostly mutated and/or conformationally altered proteins,
may elicit an HSPs response; (3) the aneuploidy (defined as abnormal chromosome num-
ber), and its associated abnormalities [54], such as chromosomal instability (CIN), could
impair HSPs expression and function. Aneuploidy alters the relative dosage of genes
on the affected chromosomes, leading to cellular stress response at least partially due to
impaired protein folding capacity. This, in turn, affects the cellular protein quality control
pathways that preserve homeostasis and induces chronic proteotoxic stress (broadly re-
ferring to the overburdening of cellular systems that maintain proper protein folding and
homeostasis) [55,56]. Consequently, the aneuploid cells would exhibit an over-production
of proteins, relative to the chaperone systems needed to fold nascent polypeptides or the
degradation systems that remove misfolded or damaged proteins. This is of particular
importance regarding the maintenance of the correct stoichiometry of macromolecular
complexes, whose subunits may be encoded by genes on different chromosomes. Further
studies are needed to more comprehensively explore the detailed molecular mechanisms
of altered HSPs expression in BC.
The prognostic analysis, performed on HSPs gene expression levels and clinical out-
come, identified two HSP-clusters, associated with a poor and good prognosis, respectively,
in line with previous reports [50,51]. Analytically, when the HSP subfamilies were consid-
ered, the chaperonins subfamily (TCP1, CCT2, CCT3, CCT4, CCT6A, CCT7, and CCT8)
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was collectively associated with poor prognosis. Accordingly, the expression levels of
different CCT members are reported as up-regulated in various cancers [57]. In particular,
it was estimated that CCT members facilitate the folding of approximately 10% of newly
synthesized proteins [58], and in cancer cells they could potentially fold more proteins,
with substrates, including oncogenic proteins and mediators of oncogenesis [59]. A more
heterogeneous involvement with prognosis was detected for HSP40 members, with 7 mem-
bers significantly associated with poor prognosis (DNAJA1, DNAJB1, DNAJB11, DNAJC2,
DNAJC5, DNAJC9, DNAJC17) and 10 members associated with good prognosis (DNAJB8,
DNAJB12, DNAJB14, DNAJC4, DNAJC5G, DNAJC10, DNAJC12, DNAJC14, DNAJB16,
and DNAJC19). HSP40 members acting as co-chaperones regulate the major functions of
other HSPs (HSP90, HSP70, and HSP60) and could be able to switch the canonical functions
of HSPs towards oncogenic roles. HSP40 members work as tumor suppressors and inhibit
tumor growth [60]. Other members have been implicated in cancer development and
metastasis, such as DNAJA1 (in glioblastoma and prostate), DNAJB11 (in ovarian tumors),
and DNAJC9 (cervical) [61].
Interestingly, the HSP-cluster associated with poor prognosis showed significant
correlations with ER-/PR-/HER+, lymph node metastases, and higher grading, identifying
more aggressive tumors. On the contrary, the HSPs cluster associated with a good prognosis
showed a significant correlation with ER+/PR+, HER-, lymph node-negative, and lower
grading tumors. Collectively, these results confirm the robustness of the identified HSP
clusters in predicting prognosis in clinical subgroups of patients.
To explore HSPs-related pathways altered in BC, genes co-expressed with HSPs were
analyzed. We found that HSPs co-expressed genes associated with poor prognosis were
enriched with cell cycle, DNA replication and cell cycle checkpoint, commonly oncogenic
processes associated with cell proliferation. Therefore, we hypothesize that HSP-networks,
affecting cell cycle, and DNA replication, may provide a robust measure of proliferation
rate and more aggressive clinical course in BC. Less robust results were obtained for the
HSPs co-expressed genes up-regulated in a good prognosis. The pathways enrichment
analysis of these genes showed that they are involved in ETM, receptors signaling (PAR-
1, c-MET, VEGFR1, VEGFR2, HER2) and Estrogen-dependent gene expression and thus
further functional investigations are needed to validate these findings.
It is well-known that miRNA can act as master players at any stage of breast cancer
development by targeting multiple mRNAs that are implicated in tumor suppressor or
oncogenic signaling pathways [62]. To gain new functional insights into the molecular
mechanisms underlying the role of HSPs in BC tumorigenesis, we screened the biological
roles of candidate miRNAs involved in HSPs-regulated networks. In these networks,
14 potential miRNAs, clustered within the miRNA network up-regulated in poor prognosis,
were identified as candidates’ hub miRNAs (hsa-mir-320b-2, hsa-mir-545, hsa-mir-941-2,
hsa-mir-651, hsa-mir-383, hsa-mir-1914, hsa-mir-570, hsa-mir-647, hsa-mir-1227, hsa-mir-
593, hsa-mir-300, hsa-mir-643, hsa-mir-626, hsa-mir-1289-1) and, accordingly with the
HSP-co-expressed gene functions, the target genes were implicated in the cell cycle. A total
of 20 miRNAs, clustered within the miRNA network up-regulated in good prognosis, were
identified as possible hub miRNAs (hsa-mir-23a, hsa-mir-143, hsa-mir-185, hsa-mir-196b,
hsa-mir-145, hsa-mir-150, hsa-mir-1228, hsa-mir-1910, hsa-mir-450a-1, hsa-mir-548i-1, hsa-
mir-1247, hsa-mir-411, hsa-mir-1299, hsa-mir-370, hsa-mir-544a, hsa-mir-1200, hsa-mir-3654,
hsa-mir-770, hsa-mir-555, hsa-mir-604), and the target genes were implicated in the negative
regulation of transcription, DNA dependent. Several of the identified miRNAs were also
differentially expressed in breast cancer than in normal tissues, emphasizing the important
role of these miRNAs in breast carcinogenesis and progression, as already reported by
several authors [63–70]. We surmise that miRNAs, related to a worse prognosis, may exert
their oncogenic functions by silencing breast onco-suppressors, while the miRNAs related
to a better prognosis may exert protective roles by silencing breast oncogenes. Further
research and validation experiments that explore the clinical and biological roles of selected
miRNAs may yield a better understanding of the mechanisms underlying breast cancer
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growth, metastasis, and survival. However, in this study, for the first time, we showed that
the HSPs deregulation in BC affected epigenetic networks involving also microRNAs.
As proteins are considered the molecular effectors, the characterization of HSPs pro-
tein expression profiles represents the best chance of better understanding their molecular
context-dependent functions. Proteomic data on HSPs expression and prognostic value
are in line with the transcriptomic results, although proteomic investigations showed a
more complex scenario in which different HSP-proteoforms (probably arising from alterna-
tively spliced RNA transcripts and post-translational modifications (PTM)) can operate
within the cancer cells, creating new functional arrangements, difficult to predict on gene
expression. Based on IHC analyses, only 5 HSP members (HSPA9, HSP90AA1, TCP1,
CCT4 and CCT6A) were significant associated with shorter overall survival, while a higher
expression level of HSPA2 was associated with a good prognosis. This stringency in the
prognostic value of HSP proteins could partly depend on the expression of multiple pro-
teoforms, probably localized in different subcellular compartments, affecting a variety
of intracellular signaling pathways. It is well-known that the HSPs activity is regulated
by PTM such as phosphorylation, acetylation, methylation, ubiquitination, glycosylation,
S-nitrosylation [71]. Since the addition and reciprocal removal of chemical groups can be
triggered very rapidly, PTMs provide an efficient switch to precisely regulate the HSPs
functions and activities. For instance, the HSP27 (HSPB1) function is modulated by phos-
phorylation at different serine residues, catalyzed by the mitogen-activated protein kinase
MAPK2 and 3 [72]. Moreover, in clinical cancer tissues, various phosphorylation patterns
of HSP27 have been found to associate with the aggressiveness of tumor phenotype [73].
Consequently, it has been proposed that HSP27 phosphorylation isoforms could also repre-
sent useful tumor markers, while a more comprehensive analysis of tissue samples will be
required. Besides, each HSP is properly localized in a specific cellular compartment(s). For
instance, HSP70 and HSP90 can be localized in the cytosol and the nucleus, grp78 (HSPA5)
in the endoplasmic reticulum. Whereas, HSP60 (HSPD1) is found in mitochondria [74].
Some HSPs can also be found on the cell surface, such as HSP60 and HSP70, especially in
lipid rafts (plasma membrane subdomains, containing high levels of cholesterol and gly-
cosphingolipids) [75]. More recently, HSPs are considered key players in the intercellular
cross-talk [76]. They may be secreted through Extracellular Vesicles (EVs), e.g., exosomes,
which derive from endosomes and multivesicular bodies. HSP27, HSP60, HSC70, HSP70,
and HSP90 were found in the extracellular environment where their role is believed to be
immunogenic and may induce either a pro- or anti-inflammatory response. For example,
EV containing HSP70 on their surface activates macrophages and natural killer cells. HSPs
can be released from cells in free, soluble form, possibly via Golgi. In this form, HSPs
circulate via blood throughout the organism and act in an endocrine fashion: [77].
5. Conclusions
Altogether, based on bioinformatics analysis and experimental validation, we pro-
vided a reliable integrated analysis of the HSPs expression pattern, prognostic value, and
potential regulatory mechanisms in breast cancer. HSPs represent a multitasking protein
family exerting multi-level functions within BC cells. HSP network is dynamic within
cancer cells whose biochemistry and function depend on cellular and environment milieu.
In this intricate scenario, two different HSP-clusters here identified might serve as a poten-
tial panel for prognosis evaluation. The usefulness of obtained data should be considered
prospectively because, in the era of personalized therapy, the molecular characterization of
the two HSP-clusters should be given the possibility to stratify patients with different prog-
noses. Moreover, several clinical trials are currently investigating the use of HSP-inhibitors
or HSP-based vaccines for cancer therapy and immunotherapy. We believe that, rather than
a single HSP member, multiple HSPs should be targeted so that they have a better chance
of reverting the clinical phenotype. In fact, the simultaneous deregulation of several HSPs
in cancer cells could be orchestrating new interactive circuits that define tumor progression.
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However, further validations are needed to judge their comprehensive prognostic impact
in BC.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-773
7/10/3/247/s1, Figure S1: Gene expression analysis of HSP members in 20 different tumors and their
corresponding normal tissues. Data were extracted for each HSP gene from ONCOMINE database.
The selected thresholds for the analyses were: p-value: 1 × 10−4; fold change: 2; gene rank: top 10%;
data type: mRNA; sample type: clinical specimens. The color depth was determined by the gene
rank (top 1%–top 5%–top 10%). The number in the colored box represents the number of analyses
meeting these thresholds. The red boxes indicate that the mRNA levels of target genes are higher
in tumor tissues than in normal tissues, while blue boxes indicate that the mRNA levels of target
genes are lower in tumor tissues than in normal tissues. (A) HSP110, HSP90 and HSP70 members; (B)
HSP60 and HSP20 members; (C,D) HSP40 members. Table S1: Prognostic value of individual HSP
members evaluated in KM plotter database. For each HSP (identified with an Affimetrix ID) survival
outcome was evaluated as Relapse Free Survival (RSF), Distant Metastasis Free Survival (DMFS),
and Overall Survival (OS). Patients were divided by the best cut-off vaue. Significant associations
with prognosis are underlined in bold. The red color indicates that the higher HSP expression is
significantly associated with a poor prognosis. The black color indicates that higher HSP expression
is significantly associated with a good prognosis. Figure S2: Survival curves of HSP members
significantly associated with poor (A–C) and good (D–F) prognosis. The analysis is shown for RFS
(A–D) OS (B–E) and DMFS (C–F) using the Kaplan-Meier Plotter database. Patients were divided
into two groups by using the best cut-off of probe expression. Table S2: Lists of positive and negative
HSPs co-expressed genes derived by GOBO, UALCAN, and bc-GenExMiner database. Pearson
correlation score was considered significant when ≥ 0.4 and ≤ −4. Figure S3. Enrichment pathway
analysis of HSPs co-expressed genes significantly correlated with prognosis. Significantly enriched
biological pathways were ranked by p-value using the FunRich 3.0 software. (A,B) The top six
biological pathways in which the HSPs co-expressed genes up-regulated in poor and good prognosis,
derived from UALCAN and bc-GenExMiner, were significantly involved. Figure S4. Construction of
HSPs-miRNAs-mRNAs network and KEGG Pathway Enrichment Analysis using miRNet. (A) HSPs
co-expressed miRNAs network up-regulated in poor prognosis; (B) HSPs co-expressed miRNAs
network up-regulated in good prognosis; (C) HSPs-miRNAs network associated with poor prognosis;
(D) HSPs-miRNAs network associated with good prognosis. In each network, yellow circles indicate
the enriched genes retrieved by KEGG pathways analysis. The size of circles and squares indicates
greater interconnection in the network (hubs miRNAs and genes). The hubs miRNAs involved in the
network are listed and the expression of each miRNA in breast cancer tissues and normal controls
was retrieved by UALCAN database. The red underlined miRNAs were significantly up-regulated in
breast cancer than normal tissues; the black underlined miRNAs were significantly down-regulated
in breast cancer than normal tissues. A p-value < 0.01 was regarded as significant. Table S3: List
of the HSP proteins identified in the proteomics maps of breast cancer tissues by Maldi-Tof. For
each protein the Abbreviated Name, the Uniprot AC, the Mowse Score, the Number of mass values
matched, the Number of mass values searched, the % Masses Matched, the % Sequence Coverage,
and the experimental MW (Da) and the pI are indicated.
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